Navigation Links
Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
Date:5/17/2009

PARIS, May 18 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its two most advanced pipeline products NXL104 and NXL103 are the subject of four posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The ECCMID conference is taking place in Helsinki between 16th and 19th May 2009.

NXL104, Novexel's broad spectrum class A and C beta-lactamase inhibitor, is the subject of one poster. Novexel is currently conducting two Phase II clinical trials in patients with complicated urinary tract infections and complicated intra-abdominal infections with NXL104 in combination with ceftazidime. The poster provides in vitro data showing that a ceftazidime/NXL104 combination is rapidly bactericidal against a range of beta-lactamase-producing strains of Enterobacteriaceae, including E. coli, and Klebsiella. Data presented also showed that one of the most important factors affecting the pharmacodynamics of the combination is maintaining a critical concentration of the inhibitor (NXL104) to suppress beta-lactamase activity. (Poster P 1463).

NXL103, a novel oral streptogramin antibiotic, is the subject of three posters at the ECCMID conference. Novexel has recently completed a successful Phase II study with NXL103 in patients with community acquired pneumonia. The first of the three posters provides in vitro data showing that NXL103 was active against methicillin resistant Staphylococcus aureus (MRSA) and organisms responsible for lower respiratory tract infections, including Streptococcus pneumoniae and Haemophilus influenzae , (Poster P 1393). The second poster contains in vivo data demonstrating that, following oral administration, NXL103 was able to kill intracellular drug-resistant and non-drug-resistant strains o
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
2. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
3. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
4. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
5. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
6. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
8. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
9. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
10. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
11. Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... , July 13, 2014  Eli Lilly and ... results from its non-clinical study in genetically engineered ... of the beta-amyloid antibody N3pG and beta-secretase inhibitor ... was more effective in removing clumps of amyloid-beta ... is thought to lead to Alzheimer,s disease (AD) ...
(Date:7/11/2014)... 11, 2014 The consumer marketing playbook ... industry sectors to better identify winning tools and ... engage with and understand consumers, as new technologies ... critical purchasing decisions. According to ... one area where organizations can observe a deep ...
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4
... Israel, November 12 Surgeons,at the University of ... can be converted to an endovascular simulator,(ANGIO Mentor(TM), ... agreed" that the simulation improved the operative flow,increased ... operative and fluoroscopy time and the amount of ...
... New Data Suggesting Need for Improved ... Annual Meeting -, EXTON, Pa., Nov. 12 ViroPharma ... from its ongoing,open-label study, showing that in this study Cinryze(TM) ... (HAE),attacks seen in the study through the date of analysis. ...
Cached Medicine Technology:Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 3ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 4ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 5ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 6
(Date:7/13/2014)... 2014 Recently, 2014QuinceaneraDresses.com, the distinguished ... its new range of gorgeous Quinceanera dresses ... demand for elegant Quinceanera outfits is huge. Therefore, ... All the company’s newly released dresses are made ... all elegant and vivid. , It is ...
(Date:7/13/2014)... 2014 Epidemiologists forecast an increase in ... from 8,062 diagnosed incident cases in 2013 to 11,568 ... Rate (AGR) of 4.35%, during the forecast period. In ... diagnosed incident cases of aGVHD in the 6MM, with ... lowest number of diagnosed incident cases of aGVHD, with ...
(Date:7/13/2014)... July 13, 2014 Wright & Schulte ... has been scheduled in July of 2015, in U.S. ... lawsuits are in the discovery process in the ... Gergel is presiding over the multidistrict litigation (MDL). The ... behalf of individuals who allege that they took the ...
(Date:7/13/2014)... Palatine, Illinois (PRWEB) July 13, 2014 Hope ... facilitating a monthly grief support group at the Tamarack Senior ... will be held at 10:30 A.M. on the 3rd Wednesdays ... July 16th, 2014 at the Tamarack Community located at 55 ... to all bereaved individuals and there is no cost for ...
(Date:7/13/2014)... Recently, iFitDress.com, one of the most popular suppliers ... added a new selection of beautiful evening dresses ... a promotion for these evening gowns. Now, everybody can ... providing thousands of graceful gowns in its online store. ... France, Italy and many other countries. They are highly ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2
... have only recently begun to speculate that whats referred to ... genome that doesnt encode for proteins and previously seemed to ... for an important reason. ,But it wasnt ... of California, San Diego (UCSD) School of Medicine have discovered ...
... counters concerns of health care providers reluctant to invest in ... be published in the July issue of the Journal of ... medical center recouped its investment in electronic health records within ... medical records in New Orleans after Hurricane Katrina is one ...
... not to board a transatlantic flight with a potentially deadly ... and two Czechs who flew with him, media said ... scare two months ago when he flew to Montreal via ... Disease Control (CDC) had said he was infected with a ...
... Medicine have found that a newly available monoclonal antibody ... cells. ,In a study, the monoclonal ... and survival in human and mouse hepotocellular cancer (HCC) ... the new findings have significant implications not only for ...
... study conducted by University of Alberta and McGill University indicate ... depression. The rate of women is much higher compared ... recently in the European Journal of Cardiovascular Nursing. ,486 ... per cent of the women had worsening depression one year ...
... air pollution stats provided by the Ontario health department is ... deaths and 6,000 hospital admissions in Toronto each year, Dr. ... of the air quality health index. , The politicians ... a new plan to control air pollution. A new tool ...
Cached Medicine News:Health News:The Importance of Junk DNA 2Health News:Electronic Medical Records can Pay You Within 16 Months 2Health News:US TB Traveler Sued Over 'reckless and Selfish Behavior' 2Health News:Monoclonal Antibody Induces Death in Liver Cancer Cells 2Health News:Female Heart Attack Victims Show Signs of Lasting Depression 2
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Elisa strip reader...
Iems Incubator/Shaker expansion module for 2 module incubator/shaker. high performance microplate incubator and orbital shaker. It's superior temperature control and efficient orbital shaking reduce ...
... Millennium 2000 is a unique microprocessor controlled ... microplates in either 96 or 384 well ... via the control panel and all are ... visible under the clear protective cover. The ...
Medicine Products: